

Ref: ADL/SE/2024-25/50
August 1, 2024

To,
 Listing/ Compliance Department
BSE Limited
 Phiroze Jeejeebhoy Towers,
 Dalal Street,
 Mumbai – 400 001
BSE CODE: 524348

To,
 Listing/ Compliance Department
National Stock Exchange of India Limited,
 “Exchange Plaza”, Plot No. C/1,
 G Block Bandra - Kurla Complex,
 Bandra (East), Mumbai – 400051
NSE SYMBOL: AARTIDRUGS

Dear Sir/Madam,

Ref: Announcement dated July 29, 2024 on US FDA EIR at manufacturing facility of the subsidiary - (Pinnacle Life Science Private Limited)

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

This is in continuation to the intimation dated July 29, 2024 and details asked by National Stock Exchange of India Limited (NSE) by email dated July 31, 2024, the information as per Para A of Part A of Schedule III under Regulation 30 of the Listing Regulations is given below:

Name of the Authority	United States Food and Drug Administration (US FDA)
Nature and details of the action(s) taken, initiated or order(s) passed	United States Food and Drug Administration (US FDA) had successfully conducted an inspection at manufacturing facility of the Company's subsidiary, Pinnacle Life Science Private Limited (Pinnacle) located at Baddi, Himachal Pradesh. Pinnacle is in receipt of the Establishment Inspection Report (EIR). EIR is a report which includes details of audit done.
Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	July 29, 2024
Details of the violation(s) / contravention(s) committed or alleged to be committed	There is no violation(s) / contravention(s) committed or alleged to be committed



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible

There are no financial or material impacts as on date. Pinnacle is in receipt of the Establishment Inspection Report (EIR) from USFDA concluding the inspection as Closed. Due to this Pinnacle can export the Formulations in US market once the products get approved by USFDA.

You are requested to take this reply on records.

Thanking you,

Yours faithfully,

FOR AARTI DRUGS LIMITED

RUSHIKESH DEOLE

COMPANY SECRETARY & COMPLIANCE OFFICER

ICSI M. No.: F12932